Efficacy of fidaxomicin therapy, after failure of vancomycin therapy, for treating a C. difficile colitis in a patient with ulcerative colitis
DOI:
https://doi.org/10.7175/cmi.v9i1S.955Keywords:
Clostridium difficile colitis, Inflammatory bowel disease, Fidaxomicin, Ulcerative colitisAbstract
Patients with inflammatory bowel diseases (IBDs) have greater risk of developing C. difficile infection (CDI). In these patients, CDI have worse outcome, may be associated with increased risk of bacteremia and candidemia and may be misdiagnosed as relapse of IBD, also because ofthe absence of typical findings of CDI at colonoscopy.
A 58-year-old man with acute ulcerative colitis treated with steroids was hospitalized for feverand recrudescence of inflammatory diarrhea. During the hospitalization, the fever was treated with broad spectrum antibiotics and systemic anti-fungal therapy. Candida mannan antigenand the molecular screening for C. difficile resulted positive. A first course of vancomycin by mouthwas unsuccessful, therefore we started a 10-day course of fidaxomicin. After five days of therapy, diarrhea disappeared. A few-week course of fluconazole therapy was performed to complete the treatment of invasive candidiasis. At six-month follow-up no relapse of CDI was documented.
References
Kaakoush NO, Day AS, Huinao KD, et al. Microbial dysbiosis in pediatric patients with Crohn's disease. J Clin Microbiol 2012; 50: 3258-66; http://dx.doi.org/10.1128/JCM.01396-12
Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-5; http://dx.doi.org/10.1073/pnas.0706625104
Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med 1998; 49: 375-90; http://dx.doi.org/10.1146/annurev.med.49.1.375
Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205-10; http://dx.doi.org/10.1136/gut.2007.128231
Ananthakrishnan AN, McGinley EL, Saeian K, et al. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 976-83; http://dx.doi.org/10.1002/ibd.21457
Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-51; http://dx.doi.org/10.1016/j.cgh.2006.12.028
Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1432-42; http://dx.doi.org/10.1002/ibd.20500
Kariv R, Navaneethan U, Venkatesh PG, et al. Impact of Clostridium difficile infection in patients with ulcerative colitis. J Crohns Colitis 2011; 5: 34-40; http://dx.doi.org/10.1016/j.crohns.2010.09.007
Mann SD, Pitt J, Springall RG, et al. Clostridium difficile infection--an unusual cause of refractory pouchitis: report of a case. Dis Colon Rectum 2003; 46: 267-70; http://dx.doi.org/10.1007/s10350-004-6533-1
Giuliano S, Guastalegname M, Jenco M, et al. Severe community onset healthcare-associated Clostridium difficile infection complicated by carbapenemase producing Klebsiella pneumoniae bloodstream infection. BMC Infect Dis 2014; 14: 475; http://dx.doi.org/10.1186/1471-2334-14-475
Guastalegname M, Russo A, Falcone M, et al. Candidemia subsequent to severe infection due to Clostridium difficile: is there a link? Clin Infect Dis 2013; 57: 772-4; http://dx.doi.org/10.1093/cid/cit362
Farina C, Arosio M, Mangia M, et al. Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis. J Clin Gastroenterol 2001; 33: 251-2; http://dx.doi.org/10.1097/00004836-200109000-00019
Horton HA, Dezfoli S, Berel D, et al. Antibiotics for treatment of Clostridium difficile infection in hospitalized patients with inflammatory bowel diseases. Antimicrob Agents Chemother 2014; 58: 5054-9; http://dx.doi.org/10.1128/AAC.02606-13
Nitzan O, Elia M, Chazan B, et al. Clostridium difficile and inflammatory bowel diseases: role in pathogenesis and implications in treatment. W J Gastroenterol 2013; 19: 7577-85; http://dx.doi.org/10.3748/wjg.v19.i43.7577
Issa M, Weber LR, Skaros S, et al. Decreasing rates of colectomy despite high rates of hospitalization in Clostridium difficile infected IBD patients: a tertiary referral center experience. Gastroenterology 2007; 132: A663 (abstract)
Cornely OA. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? Clin Microbiol Infect 2012; 18 Suppl 6: 28-35; http://dx.doi.org/10.1111/1469-0691.12012
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)